Related Experiment Videos
Transscleral diode laser photocoagulation in refractory glaucoma
V Pucci1, G Marchini, E Pedrotti
1Department of Neurologic Science and Vision, Eye Clinic, University of Verona, Italy. vincenzo.pucci@tiscalinet.it
Summary
Contact transscleral diode laser cyclophotocoagulation (DLPC) effectively lowers intra-ocular pressure (IOP) in refractory glaucoma patients. This treatment also reduces medication needs and is relatively safe, though multiple sessions may be required.
Area of Science:
- Ophthalmology
- Glaucoma Research
- Surgical Innovation
Background:
- Refractory glaucoma presents significant treatment challenges.
- Medical and surgical options are often limited for these patients.
Purpose of the Study:
- To evaluate the efficacy of contact transscleral diode laser cyclophotocoagulation (DLPC).
- To assess the impact of DLPC on intra-ocular pressure (IOP) and visual acuity in refractory glaucoma.
Main Methods:
- A cohort of 36 patients (37 eyes) with refractory glaucoma underwent DLPC.
- Follow-up averaged 14 months, analyzing IOP, visual acuity, and complications.
Main Results:
- Mean IOP decreased from 33.1 mmHg pre-treatment to 21 mmHg post-treatment.
- Average glaucoma medications reduced from 4.4 to 2.4.
- Visual acuity remained stable in 67.5% of eyes; no serious complications were reported.
Conclusions:
- DLPC is an effective treatment for lowering IOP in refractory glaucoma.
- The procedure reduces the need for antiglaucoma medications and is relatively safe.
- Multiple DLPC treatments may be necessary for optimal IOP control.